Soligenix forms Medical Advisory Board for Behcet’s Disease

Soligenix announced the formation of a Medical Advisory Board – MAB – to provide medical/clinical strategic guidance to the company as it advances the clinical development of SGX945 for the treatment of Behcet’s Disease. The FDA had granted Fast Track designation for dusquetide in the treatment of oral lesions of Behcet’s Disease. Comprised of rheumatologists with experience in Behcet’s Disease, the MAB will play an advisory role in the conduct of the upcoming Phase 2a clinical study, as well as in the design of subsequent clinical studies and associated regulatory interactions with health authorities. The MAB will provide feedback, input and guidance on clinical strategies and their implementation, as well as on other critical items, such as health economics and reimbursement, to assist Soligenix in meeting the needs of patients suffering from Behcet’s Disease.